Form 4: Delcath COO Martha Rook Awarded Equity Grants

Delcath Systems' Chief Operating Officer, Martha S. Rook, received stock options and restricted stock units as part of her compensation.

Summary

• Martha S. Rook, Chief Operating Officer of Delcath Systems, Inc. (DCTH), was granted 56,500 stock options and 28,250 Restricted Stock Units (RSUs).
• The stock options have an exercise price of $9.4 per share and will vest at a rate of 1/36th per month, beginning February 17, 2026, over three years, expiring on February 17, 2036.
• The RSUs will vest in installments: one-third on February 17, 2027, with the remaining two-thirds vesting in equal annual installments over the subsequent two years.
• Both awards are subject to Ms. Rook's continuous employment with Delcath Systems, Inc. and are issued under the company's 2020 Omnibus Equity Incentive Plan.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral to slightly positive event, representing routine executive compensation that aligns management incentives with shareholder interests, without indicating any immediate operational or financial changes.

Positives

• The equity grants align the Chief Operating Officer's interests with those of shareholders, incentivizing long-term performance and retention.
• The awards are part of a standard compensation package, reflecting ongoing commitment to executive incentives.

Negatives

• The issuance of new equity awards could lead to minor dilution for existing shareholders upon vesting and exercise, though this is typical for executive compensation plans.

Risks

• The value of the stock options and RSUs is contingent on the future performance of Delcath Systems' stock price.
• Vesting of the awards is subject to Martha S. Rook's continuous service, meaning unvested portions would be forfeited if her employment ceases.

Future Outlook

The grants indicate a long-term incentive structure for the Chief Operating Officer, with vesting schedules extending through February 2029 for RSUs and February 2036 for stock options, contingent on continued employment and company performance.

Management Comments

• The awards are made pursuant to the Delcath Systems, Inc. 2020 Omnibus Equity Incentive Plan, as amended, reflecting the company's established compensation framework.

Industry Context

StockSavvy.ai notes that equity grants to executive officers are a standard practice across industries, particularly in biotechnology and medical device sectors like Delcath Systems, to attract, retain, and motivate key talent by aligning their financial interests with long-term shareholder value creation.

Comparison to Industry Standards

• The structure of these equity grants, including a mix of stock options and RSUs with multi-year vesting schedules, is consistent with common executive compensation practices in the U.S. biotechnology and pharmaceutical industries.
• Companies such as Amgen (AMGN) and Gilead Sciences (GILD) frequently utilize similar long-term incentive plans to compensate their senior executives, often tying a significant portion of total compensation to equity performance.

Corporate Governance

Related Party Transactions

• The equity grants to Martha S. Rook, the Chief Operating Officer, constitute a related party transaction between the company and a key executive, as is typical for executive compensation.

Stakeholder Impact

• Shareholders: Potential for minor dilution upon vesting and exercise of the equity awards, but also benefits from increased alignment of executive incentives with long-term company performance.
• Employees: The grants to a senior executive may signal stability and a commitment to retaining key talent within the organization.

Next Steps

• The stock options will begin vesting monthly from February 17, 2026.
• The Restricted Stock Units will begin vesting on February 17, 2027, with subsequent annual installments.

Key Dates

Keywords

Delcath Systems, DCTH, Martha S. Rook, Chief Operating Officer, Stock Options, Restricted Stock Units, RSU, Equity Incentive Plan, Executive Compensation, Insider Transaction, Form 4